Cediranib

also known as AZD2171 · cediranib maleate · Recentin · RECENTIN TM · AZD-2171 MALEATE · Cediranib maleat · RECENTINÔ · ZD-2171

Small molecule targets KIT

Developed for: colorectal cancer · non-small cell lung carcinoma · lung cancer · adult glioblastoma · gliosarcoma · ovarian cancer · ovarian endometrioid adenocarcinoma · primary peritoneal serous adenocarcinoma
+152 more
· renal cell carcinoma · cancer · giant cell glioblastoma · neoplasm · alveolar soft part sarcoma · breast cancer · fallopian tube cancer · fallopian tube clear cell adenocarcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube serous adenocarcinoma · fallopian tube transitional cell carcinoma · glioblastoma · male breast carcinoma · ovarian clear cell adenocarcinoma · ovarian seromucinous carcinoma · ovarian serous adenocarcinoma · ovarian transitional cell carcinoma · primary peritoneal carcinoma · prostate adenocarcinoma · sarcomatoid mesothelioma · small cell lung carcinoma · undifferentiated ovarian carcinoma · adult hepatocellular carcinoma · cervical cancer · cutaneous melanoma · endometrial cancer · endometrial serous adenocarcinoma · fallopian tube carcinoma · malignant epithelial tumor of ovary · malignant epithelioid mesothelioma · metastatic malignant neoplasm · ovarian carcinoma · rectal carcinoma · refractory malignant neoplasm · triple-negative breast carcinoma · acral lentiginous melanoma · acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with t(8;21)(q22;q22) translocation · adult anaplastic ependymoma · adult brainstem glioma · adult T-cell leukemia/lymphoma · anaplastic astrocytoma · anaplastic large cell lymphoma · anaplastic oligodendroglioma · angioimmunoblastic T-cell lymphoma · atypical teratoid rhabdoid tumor · B-cell chronic lymphocytic leukemia · biliary tract neoplasm · brain neoplasm · Burkitt lymphoma · carcinosarcoma · castration-resistant prostate carcinoma · cerebellar astrocytoma · childhood brain meningioma · childhood brain stem glioma · childhood central nervous system germ cell tumor · childhood central nervous system primitive neuroectodermal neoplasm · childhood cerebral astrocytoma · childhood malignant neoplasm · childhood medulloblastoma · childhood oligodendroglioma · childhood spinal cord tumor · cholangiocarcinoma · clear cell renal carcinoma · colon carcinoma · endometrial adenosquamous carcinoma · endometrial clear cell adenocarcinoma · endometrial mixed adenocarcinoma · endometrial undifferentiated carcinoma · endometrioid adenocarcinoma · exocrine pancreatic carcinoma · extranodal nasal NK/T cell lymphoma · fallopian tube mucinous adenocarcinoma · female breast carcinoma · gallbladder carcinoma · gastric cancer · gastrointestinal stromal tumor · grade II meningioma · grade III lymphomatoid granulomatosis · grade III meningioma · hairy cell leukemia · head and neck neoplasm · hepatosplenic T-cell lymphoma · high grade malignant neoplasm · Hodgkins lymphoma · hormone-resistant prostate carcinoma · hypopharynx squamous cell carcinoma · intestinal obstruction · intraocular lymphoma · iris melanoma · large-cell immunoblastic lymphoma · larynx verrucous carcinoma · leiomyosarcoma · lentigo maligna melanoma · major salivary gland carcinoma · malignant pleural mesothelioma · MALT lymphoma · mantle cell lymphoma · medium/large size posterior uveal melanoma · metastasis from malignant tumor of colon · metastatic malignant neoplasm in the brain · metastatic melanoma · metastatic prostate carcinoma · metastatic squamous cell carcinoma · mycosis fungoides and variants · myelodysplastic syndrome · myeloid leukemia · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · neurofibroma of spinal cord · neurofibromatosis type 1 · nodal marginal zone B-cell lymphoma · ocular melanoma with extraocular extension · optic pathway glioma · oropharynx squamous cell carcinoma · ovarian germ cell tumor · ovarian neoplasm · ovarian serous surface papillary adenocarcinoma · ovarian serous tumor · pancreatic adenocarcinoma · pancreatic ductal adenocarcinoma · pediatric infratentorial ependymoma · pediatric supratentorial ependymoma · periampullary adenocarcinoma · peripheral T-cell lymphoma, not otherwise specified · peritoneum cancer · pineoblastoma · plexiform neurofibroma · primary cutaneous B-cell lymphoma · prostate cancer · prostate neuroendocrine neoplasm · salivary gland squamous cell carcinoma · small intestine lymphoma · small size posterior uveal melanoma · soft tissue sarcoma · splenic marginal zone lymphoma · subependymal giant cell astrocytoma · superficial spreading melanoma · T-cell large granular lymphocyte leukemia · testicular lymphoma · thyroid gland papillary carcinoma · thyroid Hurthle cell carcinoma · tongue carcinoma · uterine adnexa cancer · uveal melanoma · verrucous carcinoma of oral cavity · Waldenstrom macroglobulinemia · breast carcinoma · peritoneal neoplasm · pleural neoplasm
Investigated by: National Cancer Institute (NCI) · AstraZeneca · NRG Oncology · NCIC Clinical Trials Group · University Health Network, Toronto · Alliance for Clinical Trials in Oncology
+30 more
· Cancer Research UK · Cardiff University · Royal Marsden NHS Foundation Trust · University College, London · Beth Israel Deaconess Medical Center · CCTU- Cancer Theme · Canadian Cancer Trials Group · Institute of Cancer Research, United Kingdom · Korean Gynecologic Oncology Group · M.D. Anderson Cancer Center · MFAR · Mario Negri Institute for Pharmacological Research · Massachusetts General Hospital · Merck Sharp & Dohme LLC · Myriad Genetic Laboratories, Inc. · National Comprehensive Cancer Network · Prof Gordon Jayson · Radiation Therapy Oncology Group · Samsung Genomic Institute · Samsung Medical Center · Seoul National University Hospital · Spanish Melanoma Group · Susana M. Campos, MD · The Christie NHS Foundation Trust · University of Cambridge · University of Glasgow · University of Manchester · University of Oxford · Wyeth is now a wholly owned subsidiary of Pfizer · Yonsei University

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed	EU (EMA)	—	progesterone-receptor positive breast cancer	—	“MAA submitted to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2015 for cediranib” astrazeneca.com ↗

Trials 99 · started per year

today

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 129 trials
Phase 1	NCT01364051	May 2011 → Jun 2019 overdue	cutaneous melanoma, metastatic melanoma, refractory malignant neoplasm	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT01160926	Jul 2010 → Oct 2013	rectal carcinoma	The Christie NHS Foundation Trust	Terminated	No outcome recorded
Phase 1	NCT01131234	May 2010 → Sep 2014	adult anaplastic ependymoma, adult brainstem glioma, adult glioblastoma, anaplastic astrocytoma +15	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00979862	Mar 2010 → May 2012	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01065662	Feb 2010 → Sep 2013	cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer +1	Susana M. Campos, MD	Completed	No outcome recorded
Phase 1	NCT00981721	Sep 2009 → May 2010	high grade malignant neoplasm	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00960349	Aug 2009 → Jan 2010	gastric cancer	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00937482	Aug 2009 → Mar 2011	male breast carcinoma, malignant colon neoplasm, melanoma, metastatic malignant neoplasm in the brain +3	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT00750841	Sep 2008 → Jul 2009 overdue	cancer	AstraZeneca	Active not recruiting	No outcome recorded
Phase 1	NCT00750425	Aug 2008 → Apr 2009	cancer	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00748891	Aug 2008 → Feb 2010	cancer	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00621361	Feb 2008 → Aug 2009	lung cancer	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00621725	Jan 2008 → Jul 2010	cancer of unknown primary site	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00539331	Sep 2007 → Sep 2008	non-small cell lung carcinoma	AstraZeneca	Terminated	No outcome recorded
Phase 1	NCT00503204	Sep 2007 → Dec 2008	brain neoplasm, glioblastoma	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00475956	May 2007 → Oct 2008	neoplasm	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00458731	May 2007 → Dec 2013	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +19	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00321581	May 2006 → Oct 2011	acute myeloid leukemia, refractory malignant neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00326664	Mar 2006 → Jul 2015	atypical teratoid rhabdoid tumor, cerebellar astrocytoma, childhood brain meningioma, childhood brain stem glioma +13	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00243347	Dec 2005 → May 2008	head and neck neoplasm, non-small cell lung carcinoma	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00343408	Nov 2005 → Sep 2007	colorectal cancer, lung cancer	NCIC Clinical Trials Group	Completed	No outcome recorded
Phase 1	NCT00503412	Nov 2005 → May 2006	metastatic malignant neoplasm	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00503477	Oct 2005 → Jul 2007	neoplasm	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00107250	Jan 2005 → Oct 2009	colorectal cancer, lung cancer	NCIC Clinical Trials Group	Completed	No outcome recorded
Phase 1	NCT00502567	Jan 2005 → Nov 2007	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00502060	Aug 2004 → Jun 2006	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00502385	Apr 2004 → ?	myeloid leukemia	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00502164	Mar 2004 → ?	prostate adenocarcinoma	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00501605	Feb 2003 → Apr 2005	neoplasm	AstraZeneca	Completed	No outcome recorded

Phase 1/25 trials · 1 met primary · 2 missed
Phase 1/2	NCT02484404	Jun 2015 → Oct 2027 expected	breast cancer, colorectal cancer	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT01208051	Sep 2010 → Feb 2020	thyroid Hurthle cell carcinoma, thyroid gland papillary carcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 1/2	NCT01116648	Apr 2010 → Oct 2018 overdue	fallopian tube carcinoma, ovarian endometrioid adenocarcinoma, ovarian serous surface papillary adenocarcinoma, primary peritoneal serous adenocarcinoma +1	National Cancer Institute (NCI)	Active not recruiting	Met primary
Phase 1/2	NCT01064648	Mar 2010 → Jun 2018 overdue	malignant epithelioid mesothelioma, malignant pleural mesothelioma, sarcomatoid mesothelioma	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 1/2	NCT00662506	Apr 2008 → Apr 2014	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 254 trials · 4 met primary · 7 missed
Phase 2	NCT04739800	Jun 2021 → Jan 2023 overdue	fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +9	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT04090567	Jul 2020 → Dec 2027 expected	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, Her2-receptor negative breast cancer	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT03741426	Jul 2020 → Dec 2027 expected	renal cell carcinoma	CCTU- Cancer Theme	Recruiting	No outcome recorded
Phase 2	NCT04184518	May 2020 → Dec 2021	metastatic malignant neoplasm, uveal melanoma	Spanish Melanoma Group	Withdrawn	No outcome recorded
Phase 2	NCT03851614	Apr 2019 → Jan 2027 expected	colorectal cancer, leiomyosarcoma, pancreatic adenocarcinoma	University Health Network, Toronto	Active not recruiting	No outcome recorded
Phase 2	NCT03699449	Nov 2018 → Sep 2022	—	Yonsei University	Unknown	No outcome recorded
Phase 2	NCT03660826	Sep 2018 → Dec 2024 overdue	endometrial mixed adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrioid adenocarcinoma	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 2	NCT03570437	May 2018 → Jan 2023	carcinosarcoma, endometrial cancer	University of Manchester	Unknown	No outcome recorded
Phase 2	NCT07648745	May 2018 → Jan 2025	fallopian tube carcinoma, intestinal obstruction, ovarian carcinoma, primary peritoneal carcinoma	Prof Gordon Jayson	Completed	No outcome recorded
Phase 2	NCT02899728	Mar 2018 → Mar 2020	small cell lung carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03334617	Dec 2017 → Sep 2024 overdue	non-small cell lung carcinoma	AstraZeneca	Active not recruiting	No outcome recorded
Phase 2	NCT02974621	Dec 2017 → Dec 2022 overdue	glioblastoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT02893917	Aug 2017 → Mar 2023 overdue	castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma, prostate neuroendocrine neoplasm	National Cancer Institute (NCI)	Active not recruiting	Met primary
Phase 2	NCT03314740	Jun 2017 → Apr 2021	ovarian neoplasm	Mario Negri Institute for Pharmacological Research	Completed	Missed primary
Phase 2	NCT03117933	Mar 2017 → Mar 2021	ovarian cancer	University of Oxford	Completed	No outcome recorded
Phase 2	NCT02889900	Jan 2017 → Aug 2019	—	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT02498613	Aug 2016 → Jun 2022 overdue	non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, small cell lung carcinoma, triple-negative breast carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT02345265	May 2016 → Jul 2022 overdue	fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma +1	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT02340611	Jun 2015 → Jun 2018	ovarian cancer	University Health Network, Toronto	Completed	No outcome recorded
Phase 2	NCT01391962	Jul 2011 → Nov 2023	alveolar soft part sarcoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT01337401	Jul 2011 → Jul 2019	alveolar soft part sarcoma	Institute of Cancer Research, United Kingdom	Unknown	Met primary
Phase 2	NCT01260688	Oct 2010 → Jan 2013	hormone-resistant prostate carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01229111	Oct 2010 → Mar 2014	cholangiocarcinoma, gallbladder carcinoma, periampullary adenocarcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT01132820	Jun 2010 → Jan 2016	endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01229930	Jun 2010 → Dec 2012	cervical cancer	University of Glasgow	Completed	No outcome recorded
Phase 2	NCT01062425	Feb 2010 → Dec 2015	adult glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	Met primary
Phase 2	NCT00942877	Jul 2009 → Sep 2018	alveolar soft part sarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00427973	May 2009 → Apr 2010	adult hepatocellular carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT00475150	May 2008 → Jul 2011	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation, myelodysplastic syndrome	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00588900	Mar 2008 → May 2010	colorectal cancer	Alliance for Clinical Trials in Oncology	Terminated	No outcome recorded
Phase 2	NCT00527124	Nov 2007 → Jul 2012	prostate adenocarcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00326599	Jun 2007 → Apr 2009	lung cancer	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 2	NCT00454805	Mar 2007 → Dec 2008	breast cancer	AstraZeneca	Completed	Missed primary
Phase 2	NCT00458978	Feb 2007 → May 2013	hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, major salivary gland carcinoma, metastatic squamous cell carcinoma +6	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00423332	Jan 2007 → Mar 2008	renal cell carcinoma	AstraZeneca	Completed	Met primary
Phase 2	NCT00436956	Oct 2006 → Feb 2010	prostate cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00410904	Oct 2006 → Jul 2013	non-small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00385203	Sep 2006 → Jun 2008	gastrointestinal stromal tumor, soft tissue sarcoma	AstraZeneca	Completed	Missed primary
Phase 2	NCT00306891	Jun 2006 → Jan 2008	cancer	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00326872	May 2006 → Aug 2011	neurofibroma of spinal cord, neurofibromatosis type 1, plexiform neurofibroma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00321724	May 2006 → May 2007	B-cell chronic lymphocytic leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00278343	Apr 2006 → Jun 2010	fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00245063	Mar 2006 → Mar 2010	small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00303862	Mar 2006 → Mar 2011	clear cell renal carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT00305656	Jan 2006 → Apr 2012	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00243061	Jan 2006 → Mar 2012	acral lentiginous melanoma, iris melanoma, lentigo maligna melanoma, medium/large size posterior uveal melanoma +3	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00278889	Jan 2006 → Nov 2007	colorectal cancer	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00238394	Dec 2005 → Mar 2007	adult hepatocellular carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00309946	Dec 2005 → Sep 2010	malignant epithelioid mesothelioma, sarcomatoid mesothelioma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT00227760	Dec 2005 → May 2013	renal cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00243074	Nov 2005 → Apr 2010	sarcomatoid mesothelioma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00264004	Nov 2005 → Jan 2007	neoplasm	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00275028	Oct 2005 → Mar 2010	fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal serous adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00244881	Sep 2005 → Aug 2007	male breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Phase 2/34 trials · 1 met primary · 2 missed
Phase 2/3	NCT02502266	May 2016 → Jun 2023 overdue	fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma +7	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 2/3	NCT00939848	Apr 2011 → Sep 2012	biliary tract neoplasm	University College, London	Completed	Missed primary
Phase 2/3	NCT00384176	Aug 2006 → Nov 2009	colorectal cancer	AstraZeneca	Completed	No outcome recorded
Phase 2/3	NCT00245154	Nov 2005 → Jul 2008	lung cancer	NCIC Clinical Trials Group	Completed	Met primary
Phase 35 trials · 3 missed
Phase 3	NCT03278717	Jun 2018 → Dec 2023	ovarian cancer	University College, London	Unknown	No outcome recorded
Phase 3	NCT02446600	Mar 2016 → Feb 2020 overdue	fallopian tube clear cell adenocarcinoma, fallopian tube transitional cell carcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma +5	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 3	NCT00795340	Feb 2009 → Jan 2012	lung cancer	NCIC Clinical Trials Group	Completed	No outcome recorded
Phase 3	NCT00777153	Oct 2008 → Apr 2010	glioblastoma	AstraZeneca	Completed	Missed primary
Phase 3	NCT00399035	Nov 2006 → Mar 2010	colorectal cancer	AstraZeneca	Completed	Missed primary
Phase not applicable2 trials
—	NCT02681237	Apr 2016 → Jan 2022	ovarian cancer	University Health Network, Toronto	Completed	No outcome recorded
—	NCT00310089	Jan 2006 → Jul 2007	breast cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Comparator or background therapy6 trials
Phase 0	NCT02855697 Background	May 2017 → Dec 2021	ovarian cancer	The Christie NHS Foundation Trust	Completed	No outcome recorded
Phase 1/2	NCT00494221 Comparator	Jun 2007 → Oct 2009	colorectal cancer	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT04487587 Comparator	Oct 2018 → Mar 2025 overdue	cervical cancer	The Clatterbridge Cancer Centre NHS Foundation Trust	Active not recruiting	No outcome recorded
Phase 2	NCT01310855 Comparator	May 2011 → May 2013	glioblastoma	University College, London	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01262612 Comparator	Apr 2010 → Dec 2011	peritoneal neoplasm, pleural neoplasm	Radboud University Medical Center	Terminated	No outcome recorded
Phase 3	NCT00532194 Comparator	Jul 2007 → Apr 2013	ovarian cancer	Medical Research Council	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 9

Date	Issuer	Release
2020-03-12	Merck Sharp & Dohme LLC	Results Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer merck.com ↗ The trial did not meet the primary endpoint in the intent-to-treat (ITT) population of a statistically significant improvement in progression-free survival (PFS) with cediranib in combination with LYNPARZA vs. platinum-based chemotherapy.
2020-03-12	AstraZeneca	Results Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer astrazeneca.com ↗ The trial did not meet the primary endpoint in the intent-to-treat (ITT) population of a statistically significant improvement in progression-free survival (PFS) with cediranib added to Lynparza versus platinum-based chemotherapy.
2016-09-21	AstraZeneca	Regulatory AstraZeneca provides update on cediranib EU marketing authorisation application astrazeneca.com ↗ The decision to withdraw the MAA was based on outstanding health authority questions that remain at this late stage of the review process.
2014-06-03	AstraZeneca	Results AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014 astrazeneca.com ↗ The data showed that the combination of the two orally-administered investigational medicines nearly doubled the time it took for patients’ tumours to progress (progression-free survival) and improved objective response rate (ORR), compared to treatment with olaparib alone.
2014-05-31	AstraZeneca	Results AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients astrazeneca.com ↗ The NCI data is extremely compelling, showing that the combination of olaparib and cediranib nearly doubled the progression-free survival benefit compared to olaparib alone.
2014-05-15	AstraZeneca	Results Continuing progress in accelerating late stage pipeline reinforces confidence in AstraZeneca’s strategy as an independent company astrazeneca.com ↗ Encouraging efficacy data from a randomised Phase II study, conducted by the US National Cancer Institute (NCI), investigating the combination of PARP inhibitor olaparib and VEGF inhibitor cediranib in high-grade serous ovarian cancer.
2014-05-14	AstraZeneca	Results AstraZeneca to demonstrate the strength and rapid acceleration of its oncology pipeline at ASCO 2014 astrazeneca.com ↗ Encouraging efficacy data shown in a randomised Phase II study, conducted by the US National Cancer Institute (NCI), investigating the combination of PARP inhibitor olaparib and VEGF inhibitor cediranib in high-grade serous ovarian cancer.
2010-05-28	AstraZeneca	Results AstraZeneca Announces Results of Recentin HORIZON II Phase III Trial in Metastatic Colorectal Cancer astrazeneca.com ↗ AstraZeneca today announced the top-line results of the HORIZON II Phase III study evaluating RECENTIN (cediranib) for the first-line treatment of metastatic colorectal cancer (mCRC).
2010-03-08	AstraZeneca	Results RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer astrazeneca.com ↗ However, the efficacy did not meet the pre-specified criteria for the primary endpoint of non-inferiority in progression-free survival.

All press releases naming this drug 9 releases

Date	Issuer	Release
2020-03-12	Merck Sharp & Dohme LLC	Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer merck.com ↗
2020-03-12	AstraZeneca	Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer astrazeneca.com ↗
2016-09-21	AstraZeneca	AstraZeneca provides update on cediranib EU marketing authorisation application astrazeneca.com ↗
2014-06-03	AstraZeneca	AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014 astrazeneca.com ↗
2014-05-31	AstraZeneca	AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients astrazeneca.com ↗
2014-05-15	AstraZeneca	Continuing progress in accelerating late stage pipeline reinforces confidence in AstraZeneca’s strategy as an independent company astrazeneca.com ↗
2014-05-14	AstraZeneca	AstraZeneca to demonstrate the strength and rapid acceleration of its oncology pipeline at ASCO 2014 astrazeneca.com ↗
2010-05-28	AstraZeneca	AstraZeneca Announces Results of Recentin HORIZON II Phase III Trial in Metastatic Colorectal Cancer astrazeneca.com ↗
2010-03-08	AstraZeneca	RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer astrazeneca.com ↗

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 108 sources stand behind the page.

Field	Value	Cited text
Known as	Cediranib	“Cediranib (RECENTIN™, AZD2171)” NCT00621361 ↗ 82 NCT01160926 ↗ NCT03334617 ↗ NCT02446600 ↗ NCT02502266 ↗ NCT01391962 ↗ NCT02340611 ↗ NCT00427973 ↗ NCT00937482 ↗ NCT01116648 ↗ NCT00384176 ↗ Show 72 more sources
Known as	AZD-2171 MALEATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL491473 ↗
Known as	AZD2171	“A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the...” NCT00777153 ↗ 23 “Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo” NCT01310855 ↗ “Single Oral Dose of Cediranib (AZD2171, Recentin™)” NCT00306891 ↗ “cediranib (RECENTIN TM, AZD2171)” NCT00981721 ↗ “cediranib (RECENTIN TM, AZD2171)” NCT00750425 ↗ “Cediranib (RECENTIN™, AZD2171)” NCT00621361 ↗ NCT00475956 ↗ NCT00503412 ↗ NCT00264004 ↗ NCT00942877 ↗ NCT00243347 ↗ Show 13 more sources
Known as	Cediranib maleat	ChEMBL registry synonym — accepted as the source's own label CHEMBL491473 ↗
Known as	cediranib maleate	“This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body...” NCT02498613 ↗ 11 “This phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain...” NCT00937482 ↗ “AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00238394 ↗ “To assess the activity of cediranib (cediranib maleate) in patients with either persistent or recurrent endometrial carcinoma.” NCT01132820 ↗ “Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies” NCT01364051 ↗ “Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day.” NCT00427973 ↗ “Patients receive olaparib PO BID and cediranib maleate PO once daily (QD).” NCT02446600 ↗ “Drug: cediranib maleate” NCT00588900 ↗ NCT01062425 ↗ NCT00458731 ↗ NCT00979862 ↗ Show 1 more source
Known as	Recentin	“A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the...” NCT00777153 ↗ 2 “Cediranib, AZD2171, RECENTIN” NCT00321581 ↗ “Recentin (Cediranib)” NCT00748891 ↗
Known as	RECENTIN TM	“cediranib (RECENTIN TM, AZD2171)” NCT00981721 ↗ 1 “cediranib (RECENTIN TM, AZD2171)” NCT00750425 ↗
Known as	RECENTINÔ	“Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours” NCT00750425 ↗
Known as	ZD-2171	ChEMBL registry synonym — accepted as the source's own label CHEMBL491473 ↗
Action	Inhibit	“Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT00227760 ↗
Modality	Small molecule	“Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor” PMID 20458050 ↗ May 2010
Route	Oral	“Given daily; orally with approximately 240 ml of water whilst in an upright position” NCT00107250 ↗
Target	KIT	“activity against all three VEGF receptors and KIT” PMID 24714778 ↗ Apr 2014